Novo Nordisk A/S (NYSE:NVO) Position Trimmed by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 57.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,614 shares of the company's stock after selling 4,798 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Novo Nordisk A/S were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter worth $29,000. Transce3nd LLC acquired a new position in Novo Nordisk A/S in the 4th quarter worth $33,000. North Capital Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter worth $27,000. Finally, Copeland Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NVO traded down $0.97 on Friday, hitting $64.32. 8,030,410 shares of the company's stock were exchanged, compared to its average volume of 9,192,994. The firm has a market cap of $287.19 billion, a PE ratio of 19.03, a P/E/G ratio of 1.29 and a beta of 0.64. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The stock has a fifty day moving average of $70.37 and a two-hundred day moving average of $74.53. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion during the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BMO Capital Markets restated a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.